{"id":"NCT01036165","sponsor":"EMD Serono","briefTitle":"A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study","officialTitle":"A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of an Electronic Autoinjector (RebiSmart™) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc) Three Times a Week (Tiw)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2010-08","completion":"2010-08","firstPosted":"2009-12-21","resultsPosted":"2010-12-22","lastUpdate":"2013-08-08"},"enrollment":103,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DEVICE","name":"RebiSmart™","otherNames":[]}],"arms":[],"summary":"The purpose of this study is to test the RebiSmart™ for\n\n* ease of use\n* multiple domains related to subject's acceptability and satisfaction\n* reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in subjects with RMS.","primaryOutcome":{"measure":"The Primary Endpoint is the Proportion of RMS Subjects Rating the RebiSmart™ Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial Questionnaire.","timeFrame":"at 12 Weeks","effectByArm":[{"arm":"Subject Disposition","deltaMin":0.78,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":99},"commonTop":["Injection Site Pain","Injection site erythema","Injection site haematoma","Influenza like illness","Multiple Sclerosis relapse"]}}